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Background: EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib, 
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival 
(PFS) in patients with non-small-cell lung cancer (NSCLC) harboring EGFR mutations. 
However, an overall view for comparing efficacy and toxicity on a meta-level is lacking. This 
study compared efficacy and toxicity of first-line treatment with five different EGFR-TKIs by 
conducting a network meta-analysis (NMA).
Methods: A systematic review was performed, aiming to find eligible literature. Data of 
PFS, overall survival (OS), objective response rate (ORR), and adverse events were extracted. 
An NMA based on Bayesian statistics was established to synthesize the efficacy and toxicity 
of all treatments.
Results: Thirteen randomized controlled trials, including data from 3,539 patients with EGFR-
mutated NSCLC, were analyzed. Rank probabilities showed that osimertinib had a potentially 
better efficacy in terms of PFS and OS compared to all other TKIs. For ORR, afatinib and 
osimertinib showed a trend of superiority compared to the other four TKIs. Furthermore, there 
was a high risk of diarrhea and rash for patients treated with afatinib or dacomitinib as well as 
a moderate risk for treatment with erlotinib, gefitinib, and osimertinib.
Conclusion: Our study showed a favorable efficacy of osimertinib in terms of PFS and OS 
compared to all other EGFR-TKIs in patients with NSCLC harboring activating EGFR muta-
tions. Furthermore, gefitinib, erlotinib, and osimertinib were associated with fewer toxicities 
compared to the other TKIs. Therefore, osimertinib is indicated as a preferable first-line TKI 
in patients with activating EGFR-mutated NSCLC.
Keywords: EGFR-TKI, gefitinib, erlotinib, afatinib, osimertinib, network meta-analysis
Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide.1 Of all lung 
cancer cases, 80–85% are non-small-cell lung cancers (NSCLC), and the majority of 
these cases are in advanced or metastatic stage (III or IV) at the time of diagnosis.2,3 
Among these patients with NSCLC, a substantial number are harboring activat-
ing EGFR mutations, ranging from 10% in Europe to 38.4% in Asia.4,5 During the 
past years, targeted therapies including tyrosine kinase inhibitors (TKIs) have been 
developed and have become standard first-line treatment for patients with EGFR 
mutation-positive NSCLC.6–8 Various trials showed higher response rates and improved 
progression-free survival (PFS) for first-line treatment with afatinib, erlotinib, and 
gefitinib compared to platinum-based doublet therapy in patients with activating 
EGFR-mutated (exon 19 deletion or exon 21 L858R mutation) NSCLC.9–18 Recently, 
Correspondence: Marscha S Holleman
erasmus School of Health Policy and 
Management, erasmus University 
Rotterdam, PO Box 1738, 3000 DR, 
Rotterdam, the Netherlands
Tel +31 10 408 9187
email holleman@eshpm.eur.nl 
Journal name: OncoTargets and Therapy
Article Designation: Review
Year: 2019
Volume: 12
Running head verso: Holleman et al
Running head recto: Holleman et al
DOI: 189438
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
5.
5.
87
.2
26
 o
n 
21
-M
ar
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2019:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1414
Holleman et al
in head-to-head trials, dacomitinib and osimertinib showed 
a significant longer PFS compared to standard EGFR-TKIs, 
while dacomitinib, a second-generation EGFR-TKI, had a 
better efficacy compared to gefitinib, and osimertinib showed 
a more favorable PFS compared to standard EGFR-TKI 
(gefitinib or erlotinib).19,20 Different EGFR-TKIs are available 
for the treatment of patients with EGFR mutation-positive 
NSCLC. However, since sufficient data from head-to-head 
trials of all these EGFR-TKIs are lacking, evidence of relative 
efficacy and toxicity of these first-line TKIs is also scarce. 
Therefore, a network meta-analysis (NMA) was performed 
to compare the efficacy and toxicity of these TKIs as first-
line treatment for patients with EGFR mutation-positive 
NSCLC. In traditional meta-analyses, the same intervention 
is compared to the same comparator in all included studies. 
NMA combines direct comparisons of interventions within 
randomized controlled trials (RCTs) with indirect compari-
sons across RCTs in multiple pairwise comparisons across a 
range of interventions. A greater share of available evidence 
is produced by using the NMA method compared to tradi-
tional meta-analysis. The NMA method enables judicious 
estimation of the relative treatment effect for comparative 
effectiveness purposes.21 Previously published NMAs did not 
show significant differences between EGFR-TKIs.22–26 New 
data for several (new) TKIs are available (ARCHER1050 and 
FLAURA trials),19,20 which may lead to new insights into the 
relative efficacy and toxicity of the EGFR-TKIs.
This study aimed to compare the efficacy and toxicity of 
first-line treatment with gefitinib, erlotinib, afatinib, dacomi-
tinib, and osimertinib for patients with activating EGFR-
mutated (exon 19 deletion or exon 21 L858R mutation) 
NSCLC by conducting an NMA of all available evidence 
in the literature.
Materials and methods
Search strategy and selection criteria
An electronic search of the PubMed, EMBASE, and 
Cochrane Library databases was conducted in order to 
find eligible studies for the NMA, following PRISMA 
guidelines.27 Eligible studies were Phase IIB/III RCTs that 
compared the efficacy and toxicity of a single TKI to another 
TKI or to standard chemotherapy as first-line treatments 
in patients with stage IIIB/IV NSCLC harboring EGFR 
mutations and in patients who were not eligible for surgery 
or radiotherapy. Standard chemotherapy was defined as 
platinum-based doublet therapy.
Papers published from 1 January, 2010 up to and including 
1 November, 2016 were included. Literature was reviewed 
by two reviewers (MSH and CAUG) and discrepancies were 
discussed. The selection of studies was based on inclusion 
and exclusion criteria. Details of the search strategy can be 
found in Appendix A. Reference lists of published systematic 
reviews and meta-analyses were checked to ensure that no 
studies were overlooked. In February 2018, the literature 
search was manually updated to ensure that no relevant 
studies were missing, as new trials have been published in 
the previous 2 years.
Data extraction and quality assessment
Information on study design, number of participants, 
patient characteristics, interventions, comparators, objective 
response rate (ORR) (complete or partial response accord-
ing to RECIST v1.1), PFS (time from randomization until 
disease progression according to RECIST v1.1 or death from 
any cause), overall survival (OS) (time from randomization 
until death from any cause), and adverse events (AEs) were 
extracted. Toxicity was scored according to the Common 
Toxicity Criteria (CTC).28 Absolute numbers of AEs were 
extracted and ORs were calculated. Diarrhea and rash (CTC 
grade 3 or higher) were included in the analyses of this study 
because these are the most common TKI-related AEs. Other 
AEs were not included in the final analysis because they are 
less impacting and are known to be relatively homogenous 
across all EGFR-TKIs.29,30 Data extraction was verified by 
the second reviewer (CAUG). For studies with more than 
one publication, the data were compared between publica-
tions. The most updated results were included in this study. 
Extracted data can be found in Appendix B.
Quality and risk of bias of the RCTs were assessed by 
using the Cochrane Collaboration’s tool for assessing risk 
of bias.31
Statistical analyses
We performed a Bayesian fixed-effects NMA in WinBUGS 
1.4 by using an adapted version of WinBUGS code from 
Dias et al32 (Appendix C). Due to the limited number of trials 
in each specific TKI group, a fixed-effects framework was 
deemed appropriate for the NMA.33–35 The outcomes of PFS, 
OS, ORR, and AEs within trials were linked in a network.
To obtain the HR of treatment a vs b, the following 
formula was used for all comparisons: HR
a,b
 = (e(∂b-∂a)), and 
chemotherapy was used as the reference treatment in the 
network (∂  chemo = 0). All other ∂’s were calculated based 
on direct and indirect evidence from the RCTs. The NMA also 
enabled us to estimate the probability of being the best treat-
ment and to rank the treatments based on these probabilities. 
Brooks–Gelman–Rubin diagnostic with WinBUGS was used 
to assess convergence, which enabled the determination of 
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the number of burn-in simulations that should be discarded 
before calculating the converged results.36
The FLAURA trial compared osimertinib with gefitinib 
or erlotinib. In this trial, no separate HRs of osimertinib vs 
gefitinib or osimertinib vs erlotinib were reported. Therefore, 
we assumed that the HRs of PFS and OS were the same 
for osimertinib vs gefitinib as they were for osimertinib vs 
erlotinib.
Results
Identification of studies and study quality
Electronic search in the databases resulted in 6,182 records, 
from which 4,664 internal and external duplicates were 
excluded. Three additional records were included after 
a manual update of the literature search. After screening 
the titles and abstracts of the remaining 1,521 records, 66 
abstracts and manuscripts were eligible for full-text reading. 
After this, 53 records were excluded and 13 unique RCTs 
were included in the analyses. The flow chart is presented 
in Figure 1.
The patient characteristics of the 13 RCTs are sum-
marized in Table 1. Eight of the 13 RCTs studied gefitinib 
(NEJ002, WJTOG3405, IPASS, First-SIGNAL, Lux-Lung 6, 
CTONG0901, ARCHER1050, and FLAURA).9–12,14,19,20,37–41 
Four RCTs studied erlotinib (OPTIMAL, EURTAC, 
ENSURE, and CTONG0901),13,15,18,40,42 three studied afatinib 
(Lux-Lung 3, Lux-Lung 6, and Lux-Lung 7),16,17,39,43,44 and 
one trial was included in the analyses for both dacomitinib 
and osimertinib (the ARCHER1050 and FLAURA study, 
respectively).19,20 Due to the heterogeneous study population 
of the IPASS and First-SIGNAL trials, we only included the 
results of the patients with activating EGFR-mutated (exon 
19 deletion or exon 21 L858R mutation) NSCLC. A total 
of 3,539 patients with EGFR mutation-positive NSCLC 
were available for analyses, 2,691 of whom were randomly 
assigned to a TKI-arm and 848 of whom received platinum-
based doublet therapy. The HRs for PFS and OS, as reported 
in the trials, are presented in Table 2. All 13 RCTs were 
classified as having acceptable quality and low risk of bias, 
according to the Cochrane Collaboration’s tool (Appendix D).
Figure 1 Flow chart of the selection of studies.
Abbreviations: RCT, randomized controlled trial; NSCLC, non-small-cell lung cancer.
Records identified through
database searching
(n=6,182)
Additional records identified
through other sources
(n=3)
Records after duplicates removed
(n=1,521)
Records screened
(n=1,521)
Records excluded
(n=1,455)
Full-text articles assessed for
eligibility
(n=66)
Studies included in
quantitative synthesis
(network meta-analysis)
(n=13)
Full-text articles excluded
(n=53)
Abstract (n=22)
Subgroup/post hoc analysis or updated results (n=15)
No (Phase IIB/III) RCT (n=7)
Non-English (n=4)
Outcomes not eligible (n=4)
No (EGFR-mutated) stage IIIB/IV NSCLC patients (n=1)
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Table 1 Characteristics of included studies regarding TKis
Trial Treatment EGFR 
patients
Male (%) Age Ethnicity Never/previous or 
current smoker (%)
Adenocarcinoma 
histology (%)
NeJ00210 Gefitinib
TC
114
114
37
36
63.9a
62.6a
Japanese 
Japanese
66/34
58/42
90
97
wJTOG340511 Gefitinib
DP
86
86
31
30
64b
64b
Japanese
Japanese
71/29
66/34
97
98
iPASS12 (Fukuoka  
et al. 2011)
Gefitinib
TC
132
129
21
21
57b
57b
Asian
Asian
94/6
94/6
95
97
First-SiGNAL14  
(Han et al. 2012)
Gefitinib
GP
26
16
12
11
57b
56.5b
Korean
Korean
N/A
N/A
N/A
N/A
OPTiMAL13  
(Zhou et al. 2011)
erlotinib
GC
82
72
41
40
57b
59b
Asian
Asian
72/28
69/31
88
86
eURTAC15 (Rosell  
et al. 2012)
erlotinib
CT
86
87
33
22
65b
65b
european
european
66/34
72/28
95
90
eNSURe18  
(wu et al. 2015)
erlotinib
GC
110
107
38 57.5b
56b
Asian
Asian
72/28
69/31
95
94
Lux-Lung 316  
(Sequist et al. 2013)
Afatinib
AP
230
115
36
33
61.5b
61b
Global
Global
67/33
70/30
100
100
Lux-Lung 617 (wu  
et al. 2014)
Afatinib
GP
242
122
36
32
58b
58b
Asian
Asian
75/25
81/19
100
100
Lux-Lung 739 (Park  
et al. 2016)
Afatinib
Gefitinib
160
159
43
33
63b
63b
Global
Global
66/34
67/33
99
99
CTONG090140  
(Yang et al. 2017)
erlotinib
Gefitinib
128
128
47
46
c N/A
N/A
82/18
73/27
96
96
ARCHeR105019 
(wu et al. 2017)
Dacomitinib
Gefitinib
227
225
36
44
62b
61b
Global
Global
65/26
64/36
N/A
N/A
FLAURA20 (Soria  
et al. 2018)
Osimertinib
Standard TKi
279
277
36
38
64b
64b
Global
Global
65/35
63/37
99
98
Notes: aMean; bmedian; cin gefitinib arm, 72 patients (56.3%) were #60 years and 56 patients (43.8%) were 60 years old, and in erlotinib arm, 71 patients (55.5%) 
were #60 years and 57 patients (44.5%) were 60 years.
Abbreviations: TKi, tyrosine kinase inhibitor; eGFR, epidermal growth factor receptor; AP, cisplatin+pemetrexed; CT, chemotherapy (not specific); DP, cisplatin+docetaxel; 
GC, carboplatin+gemcitabine; GP, cisplatin+gemcitabine; TC, carboplatin+paclitaxel; N/A, not available.
Table 2 HRs for PFS and OS of randomized studies in patients with eGFR-mutated advanced NSCLC treated with TKis
Trial Treatment Control Primary  
end point
HR (95% CI)
PFS OS
NeJ002a,10 (Maemondo et al. 2010) Gefitinib TC PFS 0.30 (0.22–0.41) 0.887 (0.634–1.241)
wJTOG3405a,11 (Mitsudomi et al. 2010) Gefitinib DP PFS 0.489 (0.336–0.710) 1.252 (0.883–1.775)
iPASSa,12 (Fukuoka et al. 2011) Gefitinib TC OS 0.48 (0.36–0.64) 1.00 (0.76–1.33)
First-SiGNALa,14 (Han et al. 2012) Gefitinib GP OS 0.544 (0.269–1.1) 1.043 (0.498–2.182)
OPTiMALa,13 (Zhou et al. 2011) erlotinib GC PFS 0.16 (0.10–0.26) 1.19 (0.83–1.71)
eURTACa,15 (Rosell et al. 2012) erlotinib CT PFS 0.37 (0.25–0.54) 1.04 (0.65–1.68)
eNSURea,18 (wu et al. 2015) erlotinib GC PFS 0.34 (0.22–0.51) 0.91 (0.63–1.31)
Lux-Lung 3a,16 (Sequist et al. 2013) Afatinib AP PFS 0.58 (0.43–0.78) 0.88 (0.66–1.17)
Lux-Lung 6a,17 (wu et al. 2014) Afatinib GP PFS 0.28 (0.20–0.39) 0.93 (0.72–1.22)
Lux-Lung 7a,39 (Park et al. 2016) Afatinib Gefitinib PFS, OS 0.73 (0.57–0.95) 0.86 (0.66–1.12)
CTONG090140 (Yang et al. 2017) erlotinib Gefitinib PFS 0.96 (0.69–1.35) 0.98 (0.67–1.42)
ARCHeR105019 (wu et al. 2017) Dacomitinib Gefitinib PFS 0.59 (0.47–0.74) 0.76 (0.582–0.993)
FLAURAa,20 (Soria et al. 2018) Osimertinib Standard TKi PFS 0.46 (0.37–0.57) 0.63 (0.45–0.88)
Note: aCrossover was allowed after progression on first-line treatment.
Abbreviations: TKi, tyrosine kinase inhibitor; eGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; PFS, progression-free survival; OS, overall 
survival; CT, chemotherapy (not specific); DP, cisplatin+docetaxel; GC, carboplatin+gemcitabine; GP, cisplatin+gemcitabine; N/A, not available; TC, carboplatin+paclitaxel; 
AP, cisplatin+pemetrexed.
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Network meta-analysis
Figure 2 shows the complete network, which comprised 
13 RCTs that studied a TKI compared to another TKI or 
chemotherapy in patients with EGFR-mutated NSCLC. 
We simulated three different chains, which produced 60,000 
iterations each. Due to a burn-in period, 30,000 iterations 
were discarded in each chain; the results were based on a 
total sample of 90,000 iterations. Brooks–Gelman–Rubin 
plots showed convergence of the parameters.
Table 3, Figure 3, and Figures S1–S6 in Appendix E 
present the NMA results for PFS, OS, ORR, and AEs (diar-
rhea and rash). Osimertinib showed a significantly better PFS 
and OS compared to all other TKIs. It also had the highest 
probability of 99% and 85%, thus showing the longest PFS 
and OS, respectively, as compared to other TKIs. Dacomi-
tinib also showed a significantly improved PFS compared 
to gefitinib, erlotinib, and afatinib. Furthermore, afatinib 
and osimertinib performed best in terms of ORR compared 
to all other drugs with a probability of 46% for both drugs. 
However, the distribution of probabilities of being the best 
did not differ significantly on ORR (Figure 3).
Diarrhea occurred significantly more often in patients 
treated with afatinib or dacomitinib. Gefitinib, erlotinib, and 
osimertinib showed a mild risk of diarrhea and chemotherapy 
had a low risk, with probabilities of being the best for 
diarrhea, with 7%, 6%, 15%, and 72%, respectively. Regard-
ing rash, occurrence was high among patients treated with 
afatinib or dacomitinib and moderate among patients treated 
with gefitinib, erlotinib, or osimertinib. The risk of rash was 
low for chemotherapy with 99% probability of being the 
best treatment.
Discussion
In patients with EGFR-mutated NSCLC, TKIs have shown 
superior efficacy compared to platinum-based doublet 
therapy.10–18 Now that we have at least five different EGFR-
TKIs, the relative efficacy and toxicity of these TKIs become 
important to help physicians choose the optimal drug for 
treatment. In contrast to meta-analysis, which only estimates 
the relative effect of the same interventions with the same 
comparators, an NMA combines direct evidence within RCTs 
with indirect evidence across RCTs to estimate the relative 
effect of multiple pairwise comparisons. In this way, the 
relative efficacy of a whole set of treatments for a disease 
can be synthesized.21 Previous NMAs tried to provide rela-
tive evidence on the efficacy of EGFR-TKIs by using only 
three or four TKIs, or by including both first- and second-line 
TKIs in the network. These studies did not show significant 
Figure 2 Complete network based on 13 RCTs.
Abbreviation: RCT, randomized controlled trial.
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differences between EGFR-TKIs in terms of efficacy and 
toxicity. Since a number of head-to-head trials between these 
drugs and data from new EGFR-TKIs are now available, 
we performed an NMA with five different TKIs (afatinib, 
dacomitinib, erlotinib, gefitinib, and osimertinib) to estimate 
their relative efficacy and toxicity as first-line treatment in 
patients with EGFR-mutated (exon 19 deletion or exon 21 
L858R mutation) NSCLC. The results of the NMA indicated 
that osimertinib was significantly more effective on PFS 
compared to all other drugs. Dacomitinib proved to be the 
second best TKI effective on PFS with a significantly better 
PFS compared to gefitinib, erlotinib, and afatinib. Osimer-
tinib also showed a significantly better efficacy in terms of 
OS compared to all other TKIs. Furthermore, AEs (diarrhea 
and rash) occurred more often in patients treated with afatinib 
Table 3 Treatment comparisons for PFS, OS (HRs [95% CI]), ORR, diarrhea, and rash (ORs [95% CI])
PFS
Chemotherapy
0.43 (0.37, 0.49)
0.36 (0.30, 0.43)
0.37 (0.31, 0.44)
0.25 (0.19, 0.33)
0.18 (0.14, 0.22)
2.34 (2.03, 2.71)
Gefitinib
0.85 (0.71, 1.02)
0.87 (0.72, 1.04)
0.59 (0.47, 0.74)
0.42 (0.34, 0.5)
2.76 (2.3, 3.34)
1.17 (0.98, 1.41)
erlotinib
1.03 (0.8, 1.3)
0.7 (0.52, 0.93)
0.49 (0.41, 0.59)
2.7 (2.27, 3.24)
1.15 (0.96, 1.39)
0.97 (0.77, 1.25)
Afatinib
0.69 (0.51, 0.91)
0.48 (0.37, 0.62)
3.95 (3.05, 5.21)
1.68 (1.35, 2.13)
1.42 (1.08, 1.93)
1.45 (1.09, 1.97)
Dacomitinib
0.71 (0.52, 0.94)
5.64 (4.58, 7.02)
2.4 (2, 2.91)
2.04 (1.7, 2.46)
2.07 (1.62, 2.69)
1.41 (1.06, 1.91)
Osimertinib
OS
Chemotherapy
1.03 (0.89, 1.19)
1.01 (0.84, 1.21)
0.9 (0.76, 1.06)
0.79 (0.58, 1.06)
0.65 (0.49, 0.84)
0.97 (0.84, 1.12)
Gefitinib
0.98 (0.80, 1.19)
0.88 (0.73, 1.05)
0.77 (0.58, 0.99)
0.63 (0.48, 0.81)
0.99 (0.83, 1.19)
1.02 (0.84, 1.24)
erlotinib
0.90 (0.71, 1.13)
0.79 (0.56, 1.08)
0.64 (0.49, 0.82)
1.11 (0.94, 1.31)
1.14 (0.96, 1.38)
1.11 (0.89, 1.42)
Afatinib
0.88 (0.63, 1.21)
0.72 (0.53, 0.96)
1.26 (0.94, 1.73)
1.3 (1.01, 1.72)
1.27 (0.93, 1.8)
1.13 (0.83, 1.59)
Dacomitinib
0.84 (0.57, 1.19)
1.54 (1.19, 2.04)
1.59 (1.24, 2.07)
1.56 (1.22, 2.03)
1.38 (1.04, 1.89)
1.20 (0.84, 1.77)
Osimertinib
ORR
Chemotherapy
3.86 (2.94, 5)
5.09 (3.66, 6.91)
6.08 (4.45, 8.1)
4.60 (3.23, 6.37)
6.18 (3.65, 9.8)
0.26 (0.2, 0.34)
Gefitinib
1.33 (0.93, 1.86)
1.59 (1.13, 2.17)
1.19 (0.96, 1.46)
1.61 (0.98, 2.49)
0.20 (0.14, 0.27)
0.75 (0.54, 1.08)
erlotinib
1.22 (0.79, 1.81)
0.92 (0.6, 1.35)
1.23 (0.75, 1.9)
0.16 (0.12, 0.22)
0.63 (0.46, 0.89)
0.82 (0.55, 1.27)
Afatinib
0.77 (0.51, 1.12)
1.04 (0.58, 1.72)
0.22 (0.16, 0.31)
0.84 (0.68, 1.04)
1.08 (0.74, 1.66)
1.30 (0.9, 1.96)
Dacomitinib
1.37 (0.79, 2.2)
0.16 (0.10, 0.27)
0.62 (0.4, 1.02)
0.82 (0.53, 1.34)
0.97 (0.58, 1.73)
0.73 (0.45, 1.26)
Osimertinib
Diarrhea
Chemotherapy
4 (0.74, 12.81)
5.11 (0.76, 17.91)
39.8 (6.71, 131.4)
53.34 (3.96, 239.4)
4.58 (0.69, 15.86)
0.25 (0.08, 1.36)
Gefitinib
1.55 (0.3, 4.82)
12.01 (2.7, 35.35)
13.36 (2.33, 44)
1.26 (0.37, 3.16)
0.2 (0.06, 1.32)
0.65 (0.21, 3.37)
erlotinib
12.03 (1.38, 46.74)
14.36 (1.1, 64.27)
1.05 (0.31, 2.63)
0.03 (0.01, 0.15)
0.08 (0.03, 0.37)
0.08 (0.02, 0.73)
Afatinib
1.71 (0.15, 7.28)
0.16 (0.02, 0.55)
0.02 (0, 0.25)
0.07 (0.02, 0.43)
0.07 (0.02, 0.91)
0.59 (0.14, 6.84)
Dacomitinib
0.17 (0.02, 0.66)
0.22 (0.06, 1.45)
0.79 (0.32, 2.67)
0.95 (0.38, 3.21)
6.39 (1.82, 43.4)
6.04 (1.52, 58.31)
Osimertinib
Rash
Chemotherapy
4.28 (1.4, 10.23)
9.18 (2.39, 24.56)
18.06 (4.51, 49.39)
1,170 (19.4, 7,267)
12.94 (2.87, 37.81)
0.23 (0.1, 0.71)
Gefitinib
2.46 (0.63, 6.74)
4.47 (1.54, 10.17)
275.4 (6.1, 1,636)
3.24 (0.92, 8.28)
0.11 (0.04, 0.42)
0.41 (0.15, 1.6)
erlotinib
2.57 (0.45, 8.35)
162 (2.34, 1,009)
1.59 (0.46, 4.03)
0.06 (0.02, 0.22)
0.22 (0.10, 0.65)
0.39 (0.12, 2.21)
Afatinib
77.97 (1.31, 477.4)
0.9 (0.17, 2.83)
0 (0, 0.05)
0 (0, 0.16)
0.01 (0, 0.43)
0.01 (0, 0.77)
Dacomitinib
0.09 (0, 0.55)
0.08 (0.03, 0.35)
0.31 (0.12, 1.08)
0.63 (0.25, 2.18)
1.11 (0.35, 5.86)
11.15 (1.82, 740.19)
Osimertinib
Abbreviations: OS, overall survival; PFS, progression-free survival; ORR, objective response rate.
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Figure 3 Distribution of probabilities of being the best for outcomes and two major 
toxicities, classified by drugs.
Note: *P,0.0001.
Abbreviations: ORR, objective response rate; OS, overall survival; PFS, progression- 
free survival.
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or dacomitinib, compared to the other treatments. Due to the 
limited number of trials per treatment arm, a fixed-effect 
NMA was considered appropriate because heterogeneity 
could not be appropriately assessed.33–35
To our knowledge, this is the first study that performed an 
NMA to compare the results between five first-line EGFR-
TKIs. Previous NMA studies failed to show significant dif-
ferences between EGFR-TKIs.22–26 By including additional 
evidence from new RCTs19,20,40 and updating results in the 
network, new results were produced, namely significant 
efficacy differences between the TKIs.
An important assumption in our study was that all 
included studies were generally similar, both clinically and 
methodologically. All 13 studies included only patients 
with activating EGFR mutations, with the percentage of 
males ranging from 11% to 47%, the median age range 
being 56–65 years, and the percentage of adenocarcinoma 
histology type ranging between 90% and 100% across the 
studies, which contributed to the homogeneity of the study 
population. Additionally, efficacy of EGFR-TKIs could be 
different when it was provided as second- or third-line treat-
ment. A previous study showed that chemotherapy might 
change the proportion of tumor cells with EGFR mutations 
within the primary tumor.45 Treatment with a TKI after 
platinum-based doublet therapy would thus probably affect 
the efficacy by inducing resistance mechanisms. Therefore, 
only first-line TKI treatments were included in our analyses 
in order to avoid such bias and to improve homogeneity.
For our analysis, the most common NMA method was 
used and, consequently, proportional hazards were assumed.32 
Since in eleven of the 13 trials the proportional hazard assump-
tion could be checked, the assumption was not violated.
The length of follow-up differed among the included 
studies. As HRs may depend on the follow-up period, find-
ings may vary when HRs are estimated at a different follow-
up period. Due to a lack of patient-level data, correction for 
the different lengths of follow-up in an NMA is not possible. 
Insight into the long-term direction of HRs can be obtained 
with a longer follow-up duration, although this will also 
induce selection bias.46
Although osimertinib showed a significant better OS 
compared to all drugs, gefitinib, erlotinib, and afatinib did not 
reveal a significant effect on OS compared to chemotherapy, 
which was similar to the individual studies. Some individual 
studies even showed OS results which were in favor of che-
motherapy due to high proportions of crossover in the chemo-
therapy arms.9,11,13–15 The minimum proportion of crossover in 
the chemotherapy arm was 59.3% in the WJTOG3405 study11 
and the maximum was 94.6% in the NEJ002 study.10 A much 
smaller proportion of patients in whom TKI was initiated 
received chemotherapy as subsequent treatment.10,11,13–17 A 
recent study suggested that patients who received chemo-
therapy or TKI after first-line TKI or first-line chemotherapy 
had a longer OS than patients who only received first-line 
therapy.42 The imbalanced subsequent treatments of the TKI 
and chemotherapy arms may have resulted in no significant 
OS differences between TKIs and chemotherapy. Therefore, 
it is questionable whether OS is an appropriate outcome 
measure in studies with substantial crossover.
Since final OS data were not available during our study 
period, the OS data of the FLAURA study were based on 
an interim analysis. Although this analysis did not show a 
formal statistical significance for OS, osimertinib seems to 
show a potential survival benefit compared to standard TKI.20 
An update of our NMA is desirable when final OS data of 
the FLAURA trial become available.
Conclusion
Our study showed that osimertinib is the most favorable 
EGFR-TKI in terms of PFS and OS. With regard to AEs, 
afatinib and dacomitinib had a higher risk of diarrhea and 
rash. Gefitinib, erlotinib, and osimertinib showed a mild risk 
of AEs. Thus, regarding its high efficacy and mild toxicity 
pattern, osimertinib is indicated as the most favorable first-
line TKI in patients with activating EGFR-mutated (exon 19 
deletion or exon 21 L858R mutation) NSCLC.
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